Neustar: DDoS Attacks Increase 180% in 2019 Compared To 2018
26.3.2020 11:00:00 EET | Business Wire | Press release
Neustar, Inc., a global information services and technology company and leader in identity resolution, announced that its Security Operations Center (SOC) saw a 168% increase in distributed denial-of-service (DDoS) attacks in Q4 2019, compared with Q4 2018, and a 180% increase overall in 2019 vs. 2018. According to Neustar’s latest cyber threats and trends report, released today, the company saw DDoS attacks across all size categories increase in 2019, with attacks sized 5 Gbps and below seeing the largest growth. These small-scale attacks made up more than three quarters of all attacks the company mitigated on behalf of its customers in 2019.
DDoS attacks taking varied forms
In 2019, the largest threat Neustar mitigated, at 587 gigabits per second (Gbps), was 31% larger than the largest attack of 2018, while the maximum attack intensity observed in 2019, 343 million packets per second (Mpps), was 252% higher than that of the most intense attack seen in 2018. However, despite these higher peaks, the average attack size (12 Gbps) and intensity (3 Mpps) remained consistent year over year. The longest single, uninterrupted attack experienced in 2019 lasted three days, 13 hours and eight minutes.
Though the number of attacks increased significantly across all size categories, small-scale attacks (5 Gbps and below) again saw the largest growth in 2019, continuing the trend from the previous year. The combination of DDoS-for-hire and botnet rental services has made DDoS attacks much easier to execute, but the fact that perpetrators seem to be in many cases choosing to engage in small-scale attacks suggests that their goal may often be something other than taking a site completely offline.
“Large, headline-making DDoS attacks do still take place, but many cybersecurity professionals believe that smaller attacks are being used simply to degrade site performance or as a smokescreen for other forms of cybercrime, such as data theft or network infiltration, which the perpetrator can execute more easily while the target’s security team is busy fighting a DDoS attack,” said Rodney Joffe, senior vice president, senior technologist and fellow at Neustar. “Furthermore, with the current move of the bulk of the workforce globally to a work from home model, we expect to see a significant increase in DDoS attacks against VPN infrastructure. This risk makes an ‘always on’ DDoS mitigation service even more critical.”
In addition to conventional DDoS attacks, which seek to exhaust bandwidth, in 2019 Neustar also observed an increase in network protocol or state exhaustion attacks, which target network infrastructure directly. Volumetric attacks continued to proliferate as well, with attackers using new DDoS vectors such as Apple Remote Management Services, Web Services Dynamic Discovery, Ubiquiti Discovery Protocol and the Constrained Application Protocol.
Said Joffe, “During the shift to teleworking at scale, we would not be surprised to see the VPN protocol ports added to these targeted attacks.”
Two- and three-vector attacks ‘just right’ for attackers
In 2019, approximately 85% of all attacks used two or more threat vectors. That number is comparable to the 2018 figure; however, the number of attacks involving two or three vectors rose from 55% to 70%, with correspondingly fewer simple single-vector attacks and complex four- and five-vector attacks, suggesting that attackers have settled into the Goldilocks zone for attacks.
Security professionals continue to view DDoS attacks as a growing threat. According to the most recent Neustar International Security Council (NISC) survey, when asked which vectors they perceived to be increasing threats during November and December 2019, senior-level cybersecurity decision-makers cited social engineering via email most frequently (59%), followed by DDoS (58%) and ransomware (56%).
Web attacks increasing
2019 saw web attacks on the rise as well. Most companies recognise the danger that slow-loading websites pose to their business and attempt to protect them with web application firewalls. In the most recent NISC survey, 98% of respondents agreed that a WAF was an essential component of their security infrastructure. However, as more and more enterprises use multiple cloud providers, often involving a mix of public and private clouds, the need for consistent security across applications and platforms is growing.
“Web attacks can be difficult to track because some variation in the performance of websites is to be expected, but they are increasingly critical for businesses to address. One survey found 45% of consumers are less likely to make a purchase when they experience a slow loading website, and 37% are less likely to return to a retailer if they experience slow loading pages,” added Joffe.
A vendor-neutral cloud WAF, coupled with DDoS protection, can eliminate a large portion of threats, allowing enterprise application experts to focus their attention on the more specialised attacks. Continuous updates from a reliable threat feed can also deliver information on bad IPs and botnet command and control (C&C) sites before they are able to damage the network.
A complimentary copy of the Neustar 2019: The Year in Review cyber threats and trends report is available here.
-ENDS-
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005046/en/
Contact information
Jenny Morris
Hotwire for Neustar
+44 (0)7393465529
neustaruk@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
